Find the targets to actually reach the disease.
Cavatar's AVATAR platform integrates AI with your proteomic and mass-spectrometry data — and our proprietary atlas of tissue-accessible targets — to surface the most druggable, deliverable targets in days, not years. No dead-ends, no guesswork.
Endothelial & caveolae antigens mapped
Of proprietary proteomic data
Nature-family publications
Validated, not just in-silico
The AI target platform for teams that can't afford to bet wrong.
- AI Target Scoring
- Mass-Spec Mining
- Accessibility Atlas
- Delivery-Aware
- Nanotech-Ready
- In-Vivo Validated
- Bioinformatics-Native
- No Dead-Ends
AI-Powered Target Scoring
Our models rank every candidate on druggability AND real vascular accessibility, so your team starts on targets a therapeutic can physically reach — at safe doses.
Mass-Spec → Insight Pipeline
Bring your raw proteomic and mass-spec data; AVATAR turns it into a ranked, evidence-backed target shortlist. No manual triage, no spreadsheet archaeology.
Delivery-Aware Discovery
Most platforms score whether a protein is present. We score whether you can get to it — the difference between a target on paper and a therapeutic that works in the body.
Every target ranked by what actually matters.
Druggability, tissue accessibility, and delivery-format fit — with the evidence behind every call.
| Target | Tissue | Accessibility | Druggability | Confidence | Recommended modality |
|---|---|---|---|---|---|
| ANXA1 (truncated) | Tumor endothelium | 92 | 88 | 94 | Antibody / ADC |
| APP2 | Lung microvascular | 90 | 87 | 91 | Antibody / bispecific |
| — | — | — | — | — | — |
| — | — | — | — | — | — |
From raw data to a ranked, validated target.
- Step 01
Connect Data
Stream your mass-spectrometry and proteomic data into an isolated workspace, or start from Cavatar's atlas of accessible targets.
- Step 02
AI Mining
Our models score every candidate for druggability, tissue accessibility, and delivery-format fit against 20+ years of in-vivo-validated data.
- Step 03
Get Ranked Targets
Receive a curated shortlist — each target with its evidence, a confidence score, and a recommended delivery route.
- Step 04
Validate & Advance
Optionally validate the top hits in vivo through our wet lab, then export the results straight into your pipeline.
Built on two decades of research published in Nature, Nature Medicine, Nature Biotechnology, Nature Nanotechnology, and the Journal of Vascular Research.
~15% injected dose per gram in tumor at 1 hour — over 100× a non-targeting antibody, with under 1% in normal organs.
Oh et al., Nature Medicine (2014)
>80% first-pass lung extraction, with lung concentration ~4× peak blood; caveolin-1 knockdown abolishes transport.
Chrastina et al., J. Vascular Research (2010) · Nayak/Chrastina et al., Nature Nanotechnology (2025)
Questions, answered.
Get early access.
We're onboarding a limited group of design-partner biotechs.